Targeted Cancer Therapies

Claire Elizabeth Powers Smith, MD, Boston University School of Medicine, Boston, Massachusetts

Vinayak Prasad, MD, MPH, University of California, San Francisco, California

Targeted cancer therapies involve chemotherapeutic agents that attack, directly or indirectly, a specific genetic biomarker found in a given cancer. Targeted oncology includes monoclonal antibodies, small molecule inhibitors, antibody-drug conjugates, and immunotherapy. For example, the monoclonal antibodies trastuzumab and pertuzumab target human epidermal growth factor receptor 2 (HER2) and are used when treating HER2-positive breast cancer. Although targeted oncology has improved survival by years for some incurable cancers such as metastatic breast and lung cancer, as few as 8% of patients with advanced cancer qualify for targeted oncology medications, and even fewer benefit. Other limitations include serious adverse events, illustrated by a 20% to 30% rate of heart attack, stroke, or peripheral vascular events among patients taking ponatinib, which is used in treating chronic myelogenous leukemia. Immune checkpoint inhibitor therapy–related adverse effects such as hypothyroidism are common, and more severe adverse events such as colitis and pneumonitis can be fatal and require immediate intervention. Drug interactions with widely prescribed medications such as antacids and warfarin are common. Additionally, financial toxicities are a problem for patients with cancer who are using costly targeted therapies. Future directions for targeted oncology include tumor-agnostic drugs, which target a given mutation and could be used in treating cancers from multiple organ types. An overview of indications, mechanism of action, and toxicities of targeted cancer therapies is offered here. (*Am Fam Physician*. 2021;103(3):155-163. Copyright © 2021 American Academy of Family Physicians.)

Targeted cancer therapy involves testing various types of cancer for genetic biomarkers that can predict the response to chemotherapeutic agents that attack the biomarkers directly or indirectly.[1,2] In the past decade, the U.S. Food and Drug Administration (FDA) has approved approximately 40 new targeted therapies for 12 different cancers[3-6] *(Table 1).* Despite this innovation, the percentage of patients with cancer who are eligible for such therapies is small. In 2018, an estimated 8.3% of 610,000 patients with advanced or metastatic cancer were eligible for targeted therapy.[7] The number of patients who benefit from these drugs is even smaller and ranges widely, depending on the tumor and drug. Targeted oncology has mainly shown benefit in the metastatic (incurable) setting, with rare success for patients treated with surgery in the local or regional setting.

Types of Targeted Therapy

Targeted therapies can be divided into four general categories: monoclonal antibodies, small molecule inhibitors, antibody-drug conjugates, and immunotherapy *(Figure 1).*

CME This clinical content conforms to AAFP criteria for CME. See CME Quiz on page 141.

Author disclosure: No relevant financial affiliations.

In general, small molecule inhibitors are oral, whereas the remaining therapies are given intravenously.

MONOCLONAL ANTIBODIES

Monoclonal antibodies are identical immunoglobulins that bind a specific antigen. Targeted oncology monoclonal antibodies are most commonly used to target an antigen on a

WHAT'S NEW ON THIS TOPIC

Targeted Cancer Therapies

In the past decade, the U.S. Food and Drug Administration has approved approximately 40 new targeted therapies for 12 different cancers.

Patients with metastatic epidermal growth factor receptor–mutated lung cancer who are treated with osimertinib (Tagrisso) live a median of 39 months, more than double the survival of similar patients who were treated with the first epidermal growth factor receptor inhibitor, erlotinib (Tarceva), between 2007 and 2011.

In 2020, the average patient out-of-pocket cost for a course of oral cancer therapy was $5,663. According to one large analysis, 20% of patients with cancer take less medication than prescribed, 19% only partially fill oral cancer therapy prescriptions, and 24% avoid filling a prescription at all.

cancer cell, leading to downregulation of oncogene signaling, or to flag tumor cells for destruction by the immune system.[8] The anti–human epidermal growth factor receptor 2 (HER2) monoclonal antibodies trastuzumab (Herceptin) and pertuzumab (Perjeta) have drastically improved outcomes for HER2-positive breast cancer, which accounts for 15% to 25% of patients with breast cancer.[9] All patients with breast cancer should undergo testing for HER2 overexpression.[10] Trastuzumab binds to HER2 on tumor cells, leading to internalization and downregulation of HER2, which is a progrowth stimulator. Trastuzumab is not as effective in treating advanced gastroesophageal cancer with HER2 overexpression, offering only a 12% overall response rate.[11] Cetuximab (Erbitux) is another monoclonal antibody used as targeted therapy; it binds to the epidermal growth factor receptor (EGFR), leading to downregulation of this potent growth modulator. Cetuximab and a similar anti-EGFR monoclonal antibody, panitumumab (Vectibix), are effective in treating metastatic colorectal cancer without mutations in the *RAS* gene because *RAS* mutations make tumor cells resistant to the effects of the EGFR blockade.[12] Detailed testing for *RAS* mutations is necessary before choosing a chemotherapy regimen for metastatic colorectal cancer.

SMALL MOLECULE INHIBITORS

Small molecule inhibitors impede a vast number of targets to slow or kill tumor cells. The majority target protein kinases that are highly active progrowth signaling initiators present in all cells and are exploited by many cancers. Examples of protein kinases targeted by small molecule inhibitors include the EGFR, anaplastic lymphoma kinase, and HER2. These protein kinases are also expressed across healthy tissues, so small molecule inhibitors also have systemic effects.

FDA-Approved Targeted Therapies for Cancer, 2010 to 2019

Drugs	Target	Drug type
Acute myelogenous leukemia		
Enasidenib (Idhifa), ivosidenib (Tibsovo)	IDH1/2	Small molecule inhibitors
Gilteritinib (Xospata), midostaurin (Rydapt)	FLT3	Small molecule inhibitors
Anaplastic thyroid cancer		
Dabrafenib (Tafinlar) plus trametinib (Mekinist)	*BRAF* and MEK	Small molecule inhibitors
Bladder cancer		
Erdafitinib (Balversa)	FGFR2/3	Small molecule inhibitor
Breast cancer		
Ado-trastuzumab emtansine (Kadcyla)	HER2	Antibody-drug conjugate
Alpelisib (Piqray)	PIK3CA	Small molecule inhibitor
Atezolizumab (Tecentriq)	PD-L1	Immunotherapy
Fam-trastuzumab deruxtecan (Enhertu)	HER2	Antibody-drug conjugate
Olaparib (Lynparza), talazoparib (Talzenna)	Poly- (adenosine diphosphate-ribose) polymerase	Small molecule inhibitors
Pertuzumab (Perjeta)	HER2	Monoclonal antibody
Chronic lymphocytic leukemia		
Ibrutinib (Imbruvica)	BTK	Small molecule inhibitor
Venetoclax (Venclexta)	BCL2	Small molecule inhibitor
Chronic myelogenous leukemia		
Bosutinib (Bosulif), dasatinib (Sprycel), nilotinib (Tasigna), ponatinib (Iclusig)	*BCR-ABL*	Small molecule inhibitors
Colorectal cancer		
Cetuximab (Erbitux)	EGFR	Monoclonal antibody
Gastroesophageal cancer		
Trastuzumab (Herceptin)	HER2	Monoclonal antibody

ALT = alanine transaminase; AST = aspartate transaminase; BCL2 = B-cell leukemia/lymphoma 2; *BCR-ABL* = a fusion gene when pieces of chromosomes 9 and 22 break off and trade places; *BRAF* = B-raf proto-oncogene; BTK = Bruton tyrosine kinase; c-KIT = gene encoding tyrosine-protein kinase KIT; CBC = complete blood count; CK = creatine kinase; CTLA-4 = cytotoxic T-lymphocyte–associated protein 4; ECG = electrocardiography; EGFR = epidermal growth factor receptor;

FDA-approved indication	Toxicities, adverse effects, precautions	Unique monitoring
Newly diagnosed and relapsed/refractory IDH1/2+ acute myelogenous leukemia	Edema, hepatotoxicity, prolonged QTc	Alkaline phosphatase, ALT, AST, CBC, chemistry, CK, ECG, total bilirubin
Newly diagnosed and relapsed/refractory FLT3+ acute myelogenous leukemia	Hepatotoxicity, prolonged QTc, rash, vomiting	Alkaline phosphatase, ALT, AST, CBC, chemistry, ECG, total bilirubin
Locally advanced or metastatic with V600E mutation	Colitis, cutaneous squamous cell cancers, fever, heart failure, hepatotoxicity, hyperglycemia, rash, thrombosis	Alkaline phosphatase, ALT, AST, blood glucose, ECG, electrolytes, renal function, skin examination, total bilirubin
Metastatic or locally advanced FGFR2/3 alterations	Central serous retinopathy, hand-foot syndrome, hyperphosphatemia, oncholysis	Eye examination, phosphate
Early stage HER2+ with residual disease after neoadjuvant treatment; metastatic HER2+	Cardiotoxicity, hepatotoxicity, interstitial lung disease, neuropathy	Alkaline phosphatase, ALT, AST, CBC, ECG, total bilirubin
PIK3CA-mutated metastatic	Dermatologic (Stevens-Johnson syndrome), hyperglycemia, severe diarrhea	A1C, blood glucose
PD-L1–positive metastatic triple negative breast cancer, in combination with chemotherapy	Colitis, endocrinopathies, hepatitis, myocarditis, pneumonitis, rash	Alkaline phosphatase, ALT, AST, blood glucose, renal function, total bilirubin, TSH
Metastatic HER2+	Cardiotoxicity, hematologic, interstitial lung disease (9%)	CBC, echocardiography
Breast cancer gene–mutated metastatic	Hematologic, increased mean corpuscular volume, pneumonitis, rare acute myelogenous leukemia	CBC, renal function
Metastatic, neoadjuvant, and adjuvant HER2+	Cardiotoxicity, diarrhea	Echocardiography
Chronic lymphocytic leukemia with 17p deletion	Atrial fibrillation, diarrhea, edema, hemorrhage	Alkaline phosphatase, ALT, AST, CBC, renal function, total bilirubin
Chronic lymphocytic leukemia with 17p deletion	Severe pancytopenia, tumor lysis syndrome	CBC, electrolytes, renal function; may require hospitalization for tumor lysis syndrome monitoring
Initial treatment: dasatinib, nilotinib, bosutinib; second-line treatment or T315I mutation: ponatinib	Arterial thrombotic events (ponatinib), diarrhea (bosutinib), edema, effusions (dasatinib), heart failure (all), hematologic, pancreatitis, prolonged QTc (nilotinib)	Alkaline phosphatase, ALT, AST, blood pressure, CBC, chemistry, ECG, glucose, lipid profile, total bilirubin; provide low-dose aspirin with ponatinib
Metastatic without mutation in *RAS*	Acneiform rash, hypomagnesemia	Electrolytes
Metastatic with HER2 overexpression	Cardiotoxicity	Echocardiography

continues

FDA = U.S. Food and Drug Administration; FGFR2/3 = fibroblast growth factor receptor 2/3; FLT3 = fms-like tyrosine kinase 3; HER2 = human epidermal growth factor receptor 2; IDH1/2 = isocitrate dehydrogenase 1/2; MEK = MAP kinase-ERK kinase; PD-1 = programmed cell death protein 1; PD-L1 = programmed cell death ligand 1; PIK3CA = phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; ROS1 = receptor tyrosine kinase encoded by gene *ROS1*; TSH = thyroid-stimulating hormone.

Many small molecule inhibitors, such as sunitinib (Sutent), are not considered targeted therapy. This drug targets multiple, wild-type intracellular kinases and does not require testing for mutations in the tyrosine kinases that it targets (e.g., vascular endothelial growth factors).[13] Alternatively, osimertinib (Tagrisso) is used only in advanced non–small cell lung cancer that contains an activating mutation in the EGFR.[14]

Small molecule inhibitors illustrate the ways in which the benefits of targeted therapies can range from transformational to marginal, depending on the cancer and target. For instance, when treated with osimertinib, patients with metastatic EGFR-mutated lung cancer live a median of 39 months,[14] which is more than double the survival compared with similar patients treated with the first EGFR inhibitor, erlotinib (Tarceva), between 2007 and 2011.[15] Similarly, patients with advanced lung cancer possessing an anaplastic lymphoma kinase fusion have a 79% response rate to the drug alectinib (Alecensa).[16] At the other end of the spectrum are drugs with modest or absent survival gains. Olaparib (Lynparza) and other poly- (adenosine diphosphate-ribose) polymerase inhibitors induce double-strand DNA breaks that cannot be repaired in breast cancer gene–mutated tumors, a mechanism termed synthetic lethality. Poly- (adenosine diphosphate-ribose) polymerase inhibitors have yet to demonstrate any improvements in survival in breast cancer gene–mutated ovarian cancer.[17]

ANTIBODY-DRUG CONJUGATES

Antibody-drug conjugates use a monoclonal antibody bound to a cytotoxic chemotherapy molecule by a peptide linker. This allows cytotoxic therapy to be delivered directly to, and cleaved inside, a tumor cell. When tumor cells undergo apoptosis, cytotoxic chemotherapy is released, killing additional nearby tumor cells. Normal host cells in the vicinity of the tumor may also be killed; this is called the bystander effect. Additionally, amounts of the cytotoxic agent can be released prematurely into the systemic circulation. Thus, antibody-drug conjugates can still result in systemic adverse effects such as fatigue, nausea, peripheral neuropathy, and thrombocytopenia.[18]

IMMUNOTHERAPY

Immunotherapy is a broad term that includes monoclonal antibodies against cytotoxic T-lymphocyte–associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), or programmed cell death ligand 1 (PD-L1), which are capable of activating the adaptive immune system against tumor cells. These immunotherapy molecules inhibit negative immune regulation and, therefore, enhance antitumor immune responses.

TABLE 1 (continued)

FDA-Approved Targeted Therapies for Cancer, 2010 to 2019

Drugs	Target	Drug type
Gastrointestinal stromal tumor		
Imatinib (Gleevec)	c-KIT	Small molecule inhibitor
Lung cancer (adenocarcinoma)		
Afatinib (Gilotrif), dacomitinib (Vizimpro), erlotinib (Tarceva), gefitinib (Iressa), osimertinib (Tagrisso)	EGFR	Small molecule inhibitors
Alectinib (Alecensa), brigatinib (Alunbrig), ceritinib (Zykadia), crizotinib (Xalkori), lorlatinib (Lorbrena)	Anaplastic lymphoma kinase	Small molecule inhibitors
Crizotinib, entrectinib (Rozlytrek)	ROS1	Small molecule inhibitors
Dabrafenib	*BRAF*	Small molecule inhibitor
Melanoma		
Binimetinib (Mektovi), cobimetinib (Cotellic), dabrafenib, encorafenib (Braftovi), trametinib, vemurafenib (Zelboraf)	*BRAF* + MEK	Small molecule inhibitors
Mismatch repair deficient solid tumors		
Ipilimumab (Yervoy), nivolumab (Opdivo), pembrolizumab (Keytruda)	PD-1 or CTLA-4	Immunotherapies
Neurotrophin receptor kinase fusion solid tumors		
Entrectinib, larotrectinib (Vitrakvi)	Neurotrophin receptor kinase	Small molecule inhibitors
Ovarian		
Niraparib (Zejula), olaparib, rucaparib (Rubraca)	Poly- (adenosine diphosphate-ribose) polymerase	Small molecule inhibitors

ALT = alanine transaminase; AST = aspartate transaminase; BCL2 = B-cell leukemia/lymphoma 2; *BCR-ABL* = a fusion gene when pieces of chromosomes 9 and 22 break off and trade places; *BRAF* = B-raf proto-oncogene; BTK = Bruton tyrosine kinase; c-KIT = gene encoding tyrosine-protein kinase KIT; CBC = complete blood count; CK = creatine kinase; CTLA-4 = cytotoxic T-lymphocyte–associated protein 4; ECG = electrocardiography; EGFR = epidermal growth factor receptor;

FDA-approved indication	Toxicities, adverse effects, precautions	Unique monitoring
Adjuvant following complete resection of c-KIT positive gastrointestinal stromal tumor	Edema, heart failure, hematologic	Alkaline phosphatase, ALT, AST, CBC, electrolytes, renal function, total bilirubin
Metastatic, EGFR exon 19 deletion or exon 21 (L858R) substitution	Diarrhea, hepatotoxicity, prolonged QTc, rash, trichiasis	Alkaline phosphatase, ALT, AST, ECG, electrolytes, renal function, total bilirubin
Metastatic, anaplastic lymphoma kinase fusion	Bradycardia, hepatotoxicity, nausea, ocular toxicity, QT prolongation, vomiting	Alkaline phosphatase, ALT, AST, CBC, renal function, total bilirubin
Metastatic, ROS1 positive	Entrectinib: cardiotoxicity, cognitive impairment, fractures, hepatotoxicity, ocular toxicity	Alkaline phosphatase, ALT, AST, ECG, echocardiography, electrolytes, total bilirubin
Metastatic, *BRAF* V600E mutation	Cutaneous squamous cell cancer, colitis, fever, heart failure, hepatotoxicity, hyperglycemia, rash, thrombosis	Alkaline phosphatase, ALT, AST, blood glucose, echocardiography, skin examination, total bilirubin
Metastatic, V600E, V600K mutation (all) Adjuvant (dabrafenib + trametinib)	*BRAF* inhibitors: alopecia, arthralgia, diarrhea, fatigue, nausea, rash MEK inhibitors: diarrhea, rash, retinopathy	Alkaline phosphatase, ALT, AST, blood glucose, echocardiography, skin examination, total bilirubin
Metastatic mismatch repair deficient solid tumor	Adrenal insufficiency, colitis, myocarditis (rare but morbid), pneumonitis, rash, thyroiditis	Alkaline phosphatase, ALT, AST, blood glucose, renal function, total bilirubin, TSH
Metastatic solid tumors with neurotrophin receptor kinase fusion protein	Cardiotoxicity, cognitive impairment, fractures, hepatotoxicity, ocular toxicity	Alkaline phosphatase, ALT, AST, ECG, echocardiography, total bilirubin
Advanced or metastatic ovarian cancer with breast cancer gene mutation	Myelodysplastic syndrome, pancytopenia	CBC

FDA = U.S. Food and Drug Administration; FGFR2/3 = fibroblast growth factor receptor 2/3; FLT3 = fms-like tyrosine kinase 3; HER2 = human epidermal growth factor receptor 2; IDH1/2 = isocitrate dehydrogenase 1/2; MEK = MAP kinase-ERK kinase; PD-1 = programmed cell death protein 1; PD-L1 = programmed cell death ligand 1; PIK3CA = phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; ROS1 = receptor tyrosine kinase encoded by gene *ROS1*; TSH = thyroid-stimulating hormone.

Immunotherapy has earned broad use. As of 2018, 43.6% of patients with cancer would be eligible for one of these drugs. Such immune checkpoint inhibitors are most commonly used in a nontargeted sense; for example, all patients with metastatic non–small cell lung cancer are likely eligible for this therapy.[19] PD-L1 expression by tumor cells or tumor-infiltrating immune cells may help predict which tumors are likely to respond to immunotherapy.[20] For example, the PD-L1 monoclonal antibody atezolizumab (Tecentriq), when combined with two cytotoxic chemotherapy drugs, improves survival by 10 months compared with placebo plus cytotoxic chemotherapy in patients with triple negative breast cancer and PD-L1 positive tumor–infiltrating immune cells; however, it did not improve survival in patients who had negative PD-L1 staining.[21] PD-L1 is not a reliable predictor of response in many types of cancer, including metastatic non–small cell lung cancer, a disease in which immunotherapy is broadly used.[22]

Testing Cancer for Actionable Mutations

Specific testing of tumors for targetable alterations is critical in many advanced cancers. The initial therapy prescribed for metastatic non–small cell lung cancer will likely be an oral small molecule inhibitor if alterations in EGFR, anaplastic lymphoma kinase, receptor tyrosine kinase encoded by gene *ROS1* (ROS1), or B-raf proto-oncogene (*BRAF*) are

FIGURE 1

Monoclonal antibody

Pertuzumab (Perjeta) inhibits HER2 dimerization

Antibody-drug conjugate

Ado-trastuzumab emtansine (Kadcyla) delivers chemotherapy to tumor cells

Small molecule inhibitor

Osimertinib (Tagrisso) inhibits downstream progrowth signaling by EGFR

EGFR = epidermal growth factor receptor; HER2 = human epidermal growth factor receptor 2; MHC II = major histocompatibility complex type II; PD-1 = programmed cell death protein 1; PD-L1 = programmed cell death ligand 1; TCR = T-cell receptor.

Four mechanisms of targeted oncology. The monoclonal antibody pertuzumab (Perjeta) inhibits HER2 dimerization, inhibiting downstream progrowth signals. The antibody-drug conjugate ado-trastuzumab emtansine (Kadcyla) links a HER2-targeted monoclonal antibody to a chemotherapy molecule, emtansine. Emtansine is internalized by the cell, leading to apoptosis. The small molecule inhibitor osimertinib (Tagrisso) binds to the intracellular portion of the EGFR, inhibiting progrowth signaling. Finally, the bottom half of the figure depicts a T-cell expressing MHC II engaged to a T-cell receptor on a tumor cell; it is unable to kill the tumor cell because PD-1 on the tumor cell is engaging the PD-L1 brake on the T-cell. Monoclonal antibodies against PD-L1 and PD-1 interrupt their binding, allowing the engaged T-cell to kill the tumor cell. *Image created with Biorender.*

of the hereditary Lynch syndrome and response to immunotherapy.[25,26] Additionally, metastatic colorectal cancer that possesses a *BRAF* mutation is more aggressive, and therapy including a *BRAF* small molecule inhibitor should be considered.[27] Other cancers for which genomic testing is critical to choosing chemotherapy include acute leukemias and metastatic bladder, breast, melanoma, ovarian, pancreatic, and prostate cancers.

Adverse Events of Targeted Therapy

Targeted oncology medications expose patients to unique toxicities, unlike the somewhat predictable adverse effects of cytotoxic chemotherapies *(Table 1)*. One such example is ponatinib (Iclusig), which is used for the treatment of more aggressive forms of chronic myelogenous leukemia. Between 20% and 30% of patients with chronic myelogenous leukemia treated with ponatinib will experience a serious adverse event such as a heart attack, stroke, or peripheral vascular event. Taking ponatinib is linked to a 1% rate of death from these events.[28] This led the FDA to briefly remove ponatinib from the market and to rerelease it with a boxed warning and reduced starting dose.[29] The increasing tendency of the FDA to approve targeted cancer therapies rapidly based on early, nonrandomized evidence, as occurred with ponatinib, means that future drugs may offer unanticipated and severe adverse events.[30] Patients taking ponatinib should also be taking low-dose aspirin if no contraindications exist.[28]

Table 2 lists possible interactions between targeted oncology medications and drugs prescribed frequently by primary care physicians. A common example is acid suppression with proton pump inhibitors when oral chemotherapeutic agents require an acidic environment for absorption.[26,31-33] Solutions may include switching to histamine H_2 receptor antagonists or spacing out medication dosing. Cytochrome P450, family 3A (CYP3A) inhibitors and inducers such as azoles, amiodarone,

detected.[15,23] If an elevated expression of PD-L1 is found in the tumor, immunotherapy may be used alone or in combination with cytotoxic chemotherapy.[24]

The initial therapy for metastatic colorectal cancer hinges on whether mutations in *RAS* are found (unlikely to benefit from EGFR monoclonal antibodies) and whether the tumor has mismatch repair deficiency, indicating a likely diagnosis

macrolide antibiotics, nondihydropyridine calcium channel blockers, antiepileptics, and antiviral medications may also lead to drug interactions.[33] Often, dose reductions in the chemotherapy agent are enough to reduce the CYP3 interactions. Some oral chemotherapy drugs interact with warfarin (Coumadin), requiring closer international normalized ratio monitoring. Safe medication reconciliation requires that the oncologist, pharmacist, and primary care physician work together closely and maintain open lines of communication.

Immunotherapy is another group of targeted therapies for which understanding the unique and unpredictable toxicities is crucial.[33] Patients taking PD-1/PD-L1 or CTLA-4 monoclonal antibodies may develop autoimmune reactions of the skin (rash: 13% to 24% with pembrolizumab [Keytruda], up to 50% with ipilimumab [Yervoy]), thyroid, and other endocrine organs (hypo- or hyperthyroidism: 9% to 18% with pembrolizumab or nivolumab [Opdivo]), and more rarely gut (colitis), liver (hepatitis), lungs (pneumonitis), heart (myocarditis), brain (encephalitis), or other organs.[34-36] Severe colitis requiring permanent discontinuation of immunotherapy and high-dose steroid treatment occurs in 3% to 6% of patients taking a combination of nivolumab and ipilimumab.[36] Severe pneumonitis occurs in 3.2% of patients with lung cancer who are being treated with pembrolizumab.[35]

Immunotherapy-related adverse events may range in severity from transient to fatal and can occur at any point after receiving an immune checkpoint therapy.[37] Delay in diagnosis and initiation of proper treatment—especially in cases of pneumonitis, colitis, and myocarditis—can be fatal. Evidence about which patients are likely to develop these toxicities is emerging, but patients with preexisting autoimmune conditions are at higher risk and are nearly universally excluded from immunotherapy candidacy.[38] Patient and caregiver education and physician recognition of these toxicities are crucial because patients need to begin steroid therapy immediately.[37]

Future Directions

Targeted oncology may be moving toward a tumor-agnostic approach, in which treatments are chosen based on specific mutations in a tumor rather than the organ of origin.[39] Pembrolizumab is approved for all cancers that have mismatch repair deficiency, a biomarker theorized to confer sensitivity to immune unmasking.[40] The neurotrophin receptor kinase inhibitors entrectinib (Rozlytrek) and larotrectinib (Vitrakvi) are approved for all solid tumors that contain neurotrophin receptor kinase fusions.[41] Such a tumor-agnostic approach has not always succeeded; vemurafenib (Zelboraf) works well for *BRAF*-mutated melanoma and colorectal cancer but appears ineffective in *BRAF*-mutated myeloma.[42] It remains uncertain what effect tumor-agnostic drug approvals will have on national or global cancer outcomes.[43]

Financial Toxicity of Targeted Therapy

Increasingly, financial toxicity is recognized as a very real adverse effect of targeted cancer therapy. Oral cancer therapies offer the convenience of pills that can be taken at home, but they often place financial burdens on patients because of out-of-pocket costs at the pharmacy. In 2020, the average out-of-pocket cost to a patient for a course of oral cancer therapy was estimated at $5,663.[44] According to one large analysis, 20% of patients with cancer take less medication than prescribed, 19% partially fill oral cancer therapy prescriptions, and 24% avoid filling a prescription at all.[45] Many patients in this study reported spending less money on food, leisure, and clothing.[45] Approximately 2% of patients will declare bankruptcy during their treatment; those with advanced disease are more likely to declare bankruptcy.[46] Bankruptcy during cancer treatment increases the risk of death.[46] Beyond financial toxicity to the individual patient, the effects of targeted oncology on escalating health care costs are significant. Immunotherapy is not cost-effective in some studies,[47] and testing of advanced cancers using next-generation sequencing assays may substantially increase the cost of care without meaningfully affecting

---

TABLE 2

Common Drug Interactions of Targeted Oncology Therapeutics

CYP3A inhibitors/inducers

Entrectinib (Rozlytrek)	Midostaurin (Rydapt)
Erdafitinib (Balversa)	Olaparib (Lynparza) and other poly- (adenosine diphosphate–ribose) polymerase inhibitors
Gefitinib (Iressa)	
Ibrutinib (Imbruvica)	
Imatinib (Gleevec)	Osimertinib (Tagrisso)
Lapatinib (Tykerb)	Ponatinib (Iclusig)
Larotrectinib (Vitrakvi)	Venetoclax (Venclexta)

Histamine H₂ blockers/PPIs

Bosutinib (Bosulif; avoid PPIs)	Erlotinib (avoid PPIs)
Crizotinib (Xalkori)	Gefitinib
Dabrafenib	Nilotinib (Tasigna; avoid PPIs)
Dasatinib (Sprycel; avoid PPIs)	Ponatinib (avoid PPIs)

Warfarin (Coumadin)

Dabrafenib (Tafinlar)	Imatinib
Erlotinib (Tarceva)	Vemurafenib (Zelboraf)
Gefitinib	Venetoclax

CYP3A = cytochrome P450, family 3A; PPI = proton pump inhibitor.

SORT: KEY RECOMMENDATIONS FOR PRACTICE

Clinical recommendation	Evidence rating	Comments
Patients with metastatic non–small cell lung cancer should receive genomic testing for epidermal growth factor receptor and anaplastic lymphoma kinase alterations and, if positive, receive targeted therapy.[14,23]	A	Consistent evidence from RCTs showing reduced mortality
Patients with metastatic colorectal cancer should receive expanded *RAS* testing and be evaluated for mismatch repair deficiency.[26]	A	Consistent evidence from RCT showing reduced mortality
Patients taking ponatinib (Iclusig) should also be taking low-dose aspirin as long as no contraindications exist.[28]	C	Expert opinion and consensus guideline in the absence of clinical trials
Patients and caregivers should receive education about immunotherapies and the clinical profile of possible immune-mediated adverse effects before initiation and throughout treatment and survivorship.[37]	C	Expert opinion and consensus guideline in the absence of clinical trials
Physicians should maintain a high level of suspicion for immune therapy–related adverse effects and consider whether prompt treatment with corticosteroids is indicated.[37]	C	Expert opinion and consensus guideline in the absence of clinical trials
Patients taking small molecule inhibitors should undergo careful medication review and may require dosage modification if they are taking other medications metabolized by CYP3A enzymes.[33]	C	Expert opinion and consensus guideline in the absence of clinical trials

CYP3A = cytochrome P450, family 3A; RCT = randomized controlled trial.

A = consistent, good-quality patient-oriented evidence; **B** = inconsistent or limited-quality patient-oriented evidence; **C** = consensus, disease-oriented evidence, usual practice, expert opinion, or case series. For information about the SORT evidence rating system, go to https://www.aafp.org/afpsort.

survival.[48] Primary care physicians can help patients by assessing for financial toxicity and by offering suggestions such as drug company assistance, charity care, and social work resources to make cancer treatment more affordable.

This article updates a previous article on this topic by Gerber.[49]

Data Sources: A PubMed search was completed in Clinical Queries using the key terms precision oncology, metastatic non–small cell lung cancer, BRCA, breast cancer, ovarian cancer, HER2-positive breast cancers; locally advanced and metastatic melanoma, metastatic colorectal cancer, chronic myeloid leukemia, NTRK fusion solid tumors, microsatellite unstable solid tumors, tumor agnostic, oral cancer drug interactions, immunotherapy toxicity, and financial toxicity. Also searched were the National Comprehensive Cancer Network guidelines, UpToDate, Essential Evidence Plus, and the U.S. Food and Drug Administration website. Search dates: March 7 and October 13, 2020.

The Authors

CLAIRE ELIZABETH POWERS SMITH, MD, is an assistant professor of medicine in the Hematology and Oncology department at Boston (Mass.) University Medical Center. At the time this article was written, she was a fellow in hematology and medical oncology at Oregon Health & Science University, Portland.

VINAYAK PRASAD, MD, MPH, is an associate professor in the Division of Epidemiology and Biostatistics at the University of California, San Francisco. At the time this article was written, he was a professor in the Department of Epidemiology/Biostatistics with a secondary appointment in hematology and oncology at Oregon Health & Science University.

Address correspondence to Claire Elizabeth Powers Smith, MD, Boston Medical Center, 820 Harrison Avenue, FGH 1002, Boston, MA 02118 (email: Claire.smith@bmc.org). Reprints are not available from the authors.

References

1. Prasad V, Gale RP. The ASCO Post. What precisely is precision oncology—and will it work? January 25, 2017. Accessed March 1, 2020. https://www.ascopost.com/issues/january-25-2017/what-precisely-is-precision-oncology-and-will-it-work/

2. Collins FS, Varmus H. A new initiative on precision medicine. *N Engl J Med*. 2015;372(9):793-795.

3. U.S. Food and Drug Administration. 2010 notifications. Updated February 13, 2018. Accessed December 18, 2019. https://www.fda.gov/drugs/resources-information-approved-drugs/2010-notifications

4. U.S. Food and Drug Administration. 2011 notifications. Updated February 13, 2018. Accessed December 18, 2019. https://www.fda.gov/drugs/resources-information-approved-drugs/2011-notifications

5. U.S. Food and Drug Administration. Hematology/oncology (cancer) approvals and safety notifications; 2016. Updated December 19, 2016. Accessed December 18, 2019. http://wayback.archive-it.org/7993/20170111064250/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm279174.htm

6. U.S. Food and Drug Administration. Hematology/oncology (cancer) approvals and safety notifications; 2020. Updated August 3, 2020. Accessed October 10, 2020. https://www.fda.gov/drugs/resources-information-approved-drugs/hematologyoncology-cancer-approvals-safety-notifications

7. Marquart J, Chen EY, Prasad V. Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology [published correction appears in *JAMA Oncol*. 2018;4(10):1439]. *JAMA Oncol*. 2018;4(8):1093-1098.

8. Singh S, Kumar NK, Dwiwedi P, et al. Monoclonal antibodies: a review. *Curr Clin Pharmacol*. 2018;13(2):85-99.

9. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. *Science*. 1989; 244(4905):707-712.

10. Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. *J Clin Oncol*. 2018;36(20):2105-2122.

11. Bang Y-J, Van Cutsem E, Feyereislova A, et al.; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA) [published correction appears in *Lancet*. 2010;376(9749):1302]. *Lancet*. 2010;376(9742):687-697.

12. Qin S, Li J, Wang L, et al. Efficacy and tolerability of first-line cetuximab plus leucovorin, fluorouracil, and oxaliplatin (FOLFOX-4) versus FOLFOX-4 in patients with *RAS* wild-type metastatic colorectal cancer: the open-label, randomized, phase III TAILOR trial. *J Clin Oncol*. 2018; 36(30):3031-3039.

13. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. *N Engl J Med*. 2013;369(8):722-731.

14. Ramalingam SS, Vansteenkiste J, Planchard D, et al.; FLAURA Investigators. Overall survival with osimertinib in untreated, *EGFR*-mutated advanced NSCLC. *N Engl J Med*. 2020;382(1):41-50.

15. Rosell R, Carcereny E, Gervais R, et al.; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC). *Lancet Oncol*. 2012;13(3):239-246.

16. Alecensa (alectinib) [package insert]. Chugai Pharmaceutical; 2017. Updated June 2018. Accessed May 1, 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208434s004lbl.pdf

17. Wiggans AJ, Cass GK, Bryant A, et al. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. *Cochrane Database Syst Rev*. 2015;(5):CD007929.

18. Thomas A, Teicher BA, Hassan R. Antibody-drug conjugates for cancer therapy. *Lancet Oncol*. 2016;17(6):e254-e262.

19. Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. *JAMA Netw Open*. 2019;2(5):e192535.

20. Yarchoan M, Albacker LA, Hopkins AC, et al. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. *JCI Insight*. 2019;4(6):e126908.

21. Schmid P, Adams S, Rugo HS, et al.; IMpassion130 Trial Investigators. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. *N Engl J Med*. 2018;379(22):2108-2121.

22. Paz-Ares L, Luft A, Vicente D, et al.; KEYNOTE-407 Investigators. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. *N Engl J Med*. 2018;379(21):2040-2051.

23. National Comprehensive Cancer Network. NCCN guidelines in oncology. Non small cell lung cancer version 8. 2020. Accessed October 13, 2020. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf

24. Mok TSK, Wu Y-L, Kudaba I, et al.; KEYNOTE-042 Investigators. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042). *Lancet*. 2019;393(10183):1819-1830.

25. National Comprehensive Cancer Network. NCCN guidelines in oncology. Colon cancer version 4. 2020. Accessed October 13, 2020. https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf

26. Iclusig (ponatinib) [package insert]. Ariad Pharmaceuticals; 2012. Accessed May 9, 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203469lbl.pdf

27. Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, binimetinib, and cetuximab in *BRAF* V600E-mutated colorectal cancer. *N Engl J Med*. 2019;381(17):1632-1643.

28. Cortes JE, Kim D-W, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. *Blood*. 2018;132(4):393-404.

29. Kim J, Nair A, Keegan P, et al. Evaluation of serious postmarket safety signals within 2 years of FDA approval for new cancer drugs. *Oncologist*. 2020;25(4):348-354.

30. Prasad V, Mailankody S. The accelerated approval of oncologic drugs: lessons from ponatinib. *JAMA*. 2014;311(4):353-354.

31. Sprycel (dasatinib) [package insert]. Bristol-Myers Squibb. Accessed May 9, 2020. https://packageinserts.bms.com/pi/pi_sprycel.pdf

32. Tarceva (erlotinib) [package insert]. Schwarz Pharma. Accessed May 9, 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021743s14s16lbl.pdf

33. Segal EM, Flood MR, Mancini RS, et al. Oral chemotherapy food and drug interactions. *J Oncol Pract*. 2014;10(4):e255-e268.

34. Opdivo (nivolumab) injection [package insert]. Bristol-Myers Squibb; 2014. Updated June 2020. Accessed August 6, 2020. https://packageinserts.bms.com/pi/pi_opdivo.pdf

35. Keytruda (pembrolizumab) injection [package insert]. Merck and Co.; 2014. Updated June 2020. Accessed August 6, 2020. https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf

36. Yervoy (ipilimumab) injection [package insert]. Bristol-Myers Squibb; 2011. Updated June 2020. Accessed August 6, 2020. https://packageinserts.bms.com/pi/pi_yervoy.pdf

37. Brahmer JR, Lacchetti C, Schneider BJ, et al.; National Comprehensive Cancer Network. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy. *J Clin Oncol*. 2018;36(17):1714-1768.

38. Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. *JAMA Oncol*. 2016;2(2):234-240.

39. Offin M, Liu D, Drilon A. Tumor-agnostic drug development. *Am Soc Clin Oncol Educ Book*. 2018;38:184-187.

40. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. *N Engl J Med*. 2015;372(26):2509-2520.

41. Drilon A, Siena S, Ou S-HI, et al. Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib. *Cancer Discov*. 2017;7(4):400-409.

42. Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple non-melanoma cancers with BRAF V600 mutations [published correction appears in *N Engl J Med*. 2018;379(16):1585]. *N Engl J Med*. 2015;373(8): 726-736.

43. Prasad V. Our best weapons against cancer are not magic bullets. *Nature*. 2020;577(7791):451.

44. Dusetzina SB, Keating NL. Mind the gap: why closing the doughnut hole is insufficient for increasing medicare beneficiary access to oral chemotherapy. *J Clin Oncol*. 2016;34(4):375-380.

45. Zafar SY, Peppercorn JM, Schrag D, et al. The financial toxicity of cancer treatment. *Oncologist*. 2013;18(4):381-390.

46. Ramsey SD, Bansal A, Fedorenko CR, et al. Financial insolvency as a risk factor for early mortality among patients with cancer. *J Clin Oncol*. 2016;34(9):980-986.

47. Verma V, Sprave T, Haque W, et al. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. *J Immunother Cancer*. 2018;6(1):128.

48. Gong J, Pan K, Fakih M, et al. Value-based genomics. *Oncotarget*. 2018; 9(21):15792-15815.

49. Gerber DE. Targeted therapies: a new generation of cancer treatments. *Am Fam Physician*. 2008;77(3):311-319. Accessed August 4, 2020. https://www.aafp.org/afp/2008/0201/p311.html